Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
Andrew Wirth, Andrew Grigg, Max Wolf, David Goldstein, Carol Johnson, Sidney Davis, Gaelle Dutu, Poppy Kypreos, Carole Smith, Andrew Kneebone, Mark Herzberg, David Joseph, John Catalano, Daniel Roos, Janey Stone, John Reynolds
LEUKEMIA & LYMPHOMA | TAYLOR & FRANCIS LTD | Published : 2011
In this prospective, multicenter, non-randomized study for patients with stage I-II Hodgkin lymphoma, group 1 (without risk-factors [RF]) had three cycles of ABVD chemotherapy (adriamycin, bleomycin, vinblastine, and dacarbazine) and group 2 (any of bulk, extranodal site, >3 regions, raised erythrocyte sedimentation rate [ESR]) and group 3 (B-symptoms) received four cycles. Involved field radiotherapy (IFRT) 30 Gy was given after adequate chemotherapy response. Five-year overall survival and freedom from progression (FFP) were 96% (95% confidence interval [CI] 91-98%) and 90% (84-94%), respectively. Five-year FFP was 97% (90-99%), 89% (75-95%), and 73% (52-86%) for groups 1, 2, and 3, respec..View full abstract
This work was supported by Amgen Australia.